- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02035566
Telehome Monitoring for Chronic Disease Management
Effectiveness of Telehome Monitoring on Quality of Life and Health Resources Utilization Among People With Chronic Disease Residing in Rural Maryland
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
While the nation's overall health status has improved over the past decade, disparities persist among racial/ethnic minorities, low-income whites, the medically under-served, and rural residents. The disparities in disease morbidity and mortality are a compelling crisis and the elimination of such disparities is a national priority. With an aging population, the changing demographics are increasing the disease burden attributable to chronic diseases.
The broad goal of this project is to evaluate the potential value of using THC technology in chronically ill patients in rural Maryland, within the broad context of social determinants of health. This builds upon a completed pilot research study in Garrett County on a small scale THC program in rural Garrett County Maryland funded by the Maryland Cigarette Restitution Fund (CRF) supported Other Tobacco Related Diseases (OTRD grant) (CBaquet PI) in collaboration with the division of cardiology and department of family medicine. This research study will look at whether the THC equipment in the home for 60 days will make a difference in the health of the patients who get the unit in their home compared to the patients who will not receive the unit for 60 days. And we will look at whether this technology will support patient monitoring in the home. The use of the technology will be evaluated to determine whether patient monitoring using THC equipment will influence the hospitalization rates or emergency department visits for the patients. Evaluation of the influence of the THC equipment on medical resource utilization in rural and medically underserved communities will be studied.
Telehome care (THC) may provide augmentation to current face to face monitoring through home visits (usual method for Center for Medicaid and Medicare Services (CMS) billable home health services) of chronically ill patients and may provide an innovative and potentially cost-effective solution to improving patients' outcomes and health care resource utilization in rural areas. THC can support the coordination of care by assessing and monitoring patients in their homes and giving health care providers appropriate feedback to assure patient compliance with discharge instructions such as medication, home care and other aspects of recommended treatment regimens. Further, THC may improve service coordination at discharge and provide ongoing monitoring/engagement of patients, which is considered essential to prevent re-hospitalizations and emergency department visits. Demonstration of the potential benefits on care pathways, and patient and provider acceptance and satisfaction with the technology requires systematic larger scale and scientifically rigorous studies.
Purpose The project's broad goals are to evaluate the effects of telehome care (THC), a form of remote patient home monitoring,(within the broad context of social determinants of health) for chronic disease management among rural residing minority, low-income white, and medically underserved patients by: (a) providing an innovative telehome care (THC) capacity and infrastructure in two Maryland rural and medically underserved communities; and (b) using the THC infrastructure to generate scientifically rigorous and high quality evidence on whether the THC technology improves patient monitoring, influences clinical outcomes, and has an impact on medical resource utilization. [NOTE: THC uses telecommunication technologies to enable home health agency clinical staff at a rural home health agency to monitor their patients in the home.]
The major aim for this study are: 1) To evaluate the impact of the 60-day in home THC monitoring on medical resource utilization (emergency department visits; re-hospitalization rates) and Quality of Life related to the management of Metabolic Syndrome/Diabetes Mellitus (DM), Chronic Heart Failure (CHF), Hypertension (HTN), and Chronic Obstructive Pulmonary Disease (COPD) compared to those patients that receive only an educational pamphlet. Secondary aim hopes to support patient education to enhance acceptability, patient independence and satisfaction.
In this study, remote in-home patient monitoring using a THC system from VitelNet (telehealth equipment vendor) will provide patient monitoring remotely or non billable services for the experimental study arm for this project in addition to routine billable home health services. This project does not substitute billable in-home monitoring of patients which is a prerequisite for enrollment into this study(conventional home health services) but provides remote monitoring for the study arm in addition to conventional/billable services delivered.
Patients are randomized to either THC use for 60 days with 60, 90 day follow up or "usual care" with 60, 90 day follow up.
In addition, new knowledge will be generated by this study on methods for conduct of health disparities research and training of non-research clinical personnel who are community based in data collection and research ethics.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Maryland
-
Hughesville, Maryland, Stany Zjednoczone, 20637
- Chesapeake-Potomac Home Health Agency
-
Oakland, Maryland, Stany Zjednoczone, 21550
- Garrett County Health Department Home Health Agency
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Home bound at a home health agency (i.e., Garrett County Health Department Home Health Agency or Chesapeake-Potomac Home Health Agency)
- Clinical diagnosis of at least one of the following: chronic obstructive pulmonary disease, chronic heart failure, uncontrolled hypertension, diabetes mellitus and taking anti-hyperglycemic oral therapy
- Able to operate the telehome care system
- Agreeable to have the telehome care system installed at residence for 60 days
- Residing in an environment where care can be provided safely
Exclusion Criteria:
- Not eligible for home health care
- With a clinical diagnosis of a medical condition other than obstructive pulmonary disease, chronic heart failure, uncontrolled hypertension, diabetes mellitus and taking anti-hyperglycemic oral therapy
- Unable to follow instructions about or be able to operate the telehome care system
- Residing in an environment that is unsafe to provide home health care
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Brak interwencji: Zwykła opieka
|
|
|
Eksperymentalny: Telehome Care Monitoring + Usual Care
|
Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Self reported Quality of life
Ramy czasowe: The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
Assessing change from baseline to 90 day evaluated.
|
The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
|
Number of emergency department visits
Ramy czasowe: The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
Assessing change from baseline to 90 day post baseline for:
|
The Outcome Measure(s) are assessing a change from Baseline and 90-day post-baseline
|
|
Re-hospitalization
Ramy czasowe: Assessing change from baseline and 90-day post-baseline
|
Assessing change from baseline to 90 day post baseline for:
|
Assessing change from baseline and 90-day post-baseline
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of contacts (visits or phone calls) with health care providers
Ramy czasowe: Assessing change from baseline and 90-day post-baseline
|
Assessing change from baseline and 90-day post-baseline
|
|
|
Adequacy of hypertension control
Ramy czasowe: Measures change from baseline and 90-day post-baseline
|
Measures change from baseline to 90 day post baseline for:adequacy of blood pressure control (<140/90 mmHg)
|
Measures change from baseline and 90-day post-baseline
|
|
Adequacy of diabetes control
Ramy czasowe: Measures change from baseline and 90-day post-baseline
|
adequacy of glycemic control of HbA1C of <7.5
|
Measures change from baseline and 90-day post-baseline
|
|
Compliance with recommended (by discharging physician/primary health professional) drug therapy use for heart failure
Ramy czasowe: Assessing change from baseline and 90-day post-baseline
|
Assessing change from baseline and 90-day post-baseline
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Claudia R Baquet, MD MPH, University of Maryland School of Medicine
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- HP-00044150
- RC2MD004800 (Grant/umowa NIH USA)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Niewydolność serca
-
Region SkaneRejestracja na zaproszenieNiewydolność serca Klasa II według New York Heart Association (NYHA). | Niewydolność serca Klasa III według New York Heart Association (NYHA).Szwecja
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... i inni współpracownicyZakończonyNiewydolność serca, skurcz | Niewydolność serca ze zmniejszoną frakcją wyrzutową | Niewydolność serca Klasa IV według New York Heart Association | Niewydolność serca Klasa III według New York Heart AssociationPolska
-
University of WashingtonAmerican Heart AssociationZakończonyNiewydolność serca, zastoinowa | Zmiana mitochondrialna | Niewydolność serca Klasa IV według New York Heart AssociationStany Zjednoczone
-
Portuguese Association of Interventional CardiologyMedtronicRekrutacyjnyCiężkie objawowe zwężenie zastawki aortalnej (zdefiniowane jako klasa New York Heart Association (NYHA) ≥ II)Portugalia
Badania kliniczne na Telehome Care Monitoring
-
University of PennsylvaniaZakończonyNadciśnienieStany Zjednoczone
-
Abbott Medical DevicesZakończonyKorzyści kliniczne w zoptymalizowanym zdalnym zarządzaniu pacjentami z niewydolnością serca (COR-HF)Leczenie zastoinowej niewydolności sercaWłochy
-
University of PennsylvaniaZakończony
-
Mayo ClinicZakończony
-
University of California, Los AngelesUniversity of California, San Diego; University of California, Davis; University... i inni współpracownicyZakończonyNiewydolność sercaStany Zjednoczone
-
Semmelweis University Heart and Vascular CenterRekrutacyjny
-
University Hospital, LimogesRekrutacyjny
-
Hospital St. Joseph, Marseille, FranceJeszcze nie rekrutacja
-
University of Colorado, DenverMallinckrodtRekrutacyjnyDziecięce skurcze, nieuleczalneStany Zjednoczone
-
University of California, San FranciscoNieznanyChoroby powiek | Opadanie powieki, powieka | Blepharoptoza | Guz powieki | Dermatochalaza | Entropium | Ektropion | Rak skóry, powieki | Zespół wiotkiej powiekiStany Zjednoczone